Allergan, Ista deal

ISTA reacquired rights to its Vitrase ovine hyaluronidase from AGN. Under a 2000 deal, AGN had worldwide rights to Vitrase outside Japan for use in the posterior segment of the eye. Now, AGN retains an option to commercialize Vitrase for the posterior segment of the eye in Europe. AGN will receive $6.5 million up front, plus an additional $3.5 million when ISTA completes a financing. AGN also is eligible for royalties. ...